Page 1

Q1-2021 Results HIGHLIGHTS Q1-2021 Sales increased by Ps . 213.2 million ; + 6.4 % year - on - year Q1-2021 EBITDA closed at Ps . 724.7 million ; + 6.8 % year - on - year Cash & Equivalents closed at Ps . 1.82 billion as of March 31 , 2021 Q1-2021 Net Debt to EBITDA ratio closed at 1.52x Capex Investments for the three months ended March 31 , 2021 reached Ps . 178.7 million . 1 ) Genomma Lab Internacional Reports First Quarter 2021 Results Mexico City , April 28 , 2021 Genomma Lab Internacional , S.A.B. de C.V. ( BMV : LAB B ) ( " Genomma Lab " or " the Company " ) , today announced its results for the first quarter ended March 31 , 2021. All figures included herein are stated in nominal Mexican pesos and have been prepared in accordance with International Financial Reporting Standards ( IFRS ) . The following tables provide an abridged Income Statement , in millions of Mexican pesos . The margin for each figure represents its ratio to net sales and the percentage change in the first quarter 2021 as compared with the same period in 2020 : Net Sales Gross Profit Operating Income EBITDA ( 1 ) Net Income Q1 2021 3,547.7 2,180.5 686.8 724.7 319.4 % Sales Comments from the CEO Genomma Lab 100.0 % 61.5 % 19.4 % 20.4 % 9.0 % Internacional Q1 2020 3,334.5 2,061.6 640.6 678.4 373.6 EBITDA defined as operating income before depreciation and amortization Var . % % Sales 100.0 % 61.8 % 19.2 % 20.3 % 11.2 % ( 14.5 % ) 6.4 % 5.8 % 7.2 % 6.8 % Mr. Jorge Luis Brake , Genomma Lab's Chief Executive Officer , commented : " We achieved a solid first quarter 2021 despite the significant impacts from COVID - 19 . Importantly , Genomma's results remain aligned with our strategic goals and objectives to drive long - term sustainable growth while maintaining robust levels of profitability and liquidity . We continue to identify exciting opportunities to capitalize fully on our Company's incredible potential , particularly related to technological and product innovation , while leveraging accelerating consumer trends including the sustained shift to wellness and self - care through trusted brands with increased digital engagement which we are confident will continue to persist even beyond the pandemic . " He added : " I'd again like to recognize Genomma's employees who have enabled us to overcome multiple challenges , as the collective power of our people drives our momentum and success . Our team has moved swiftly and decisively to serve our customers and communities at this critical time . 2021 is our team's year , therefore , we remain aligned with the Company's mission : to empower people to have excellent health and well - being . " www.genommalab.com/inversionistas/ 1